Studies on hbk (ii) serum and sputum levels of hbk and its therapeutic efficacy on respiratory tract and urinary tract infections by drip intravenous infusion

HBK was drip-infused intravenously with a dose of 75 mg to a patient of diffuse panbronchiolitis, and then the serum at the end of drip intravenous infusion and the sputum for two hours from the end of drip infusion were stored at —80°C. These serum and sputum levels of HBK were measured by bioassay method. The serum level was 6. 76 μg/ml and the sputum level was 0.67 μg/ml. Six patients suffering from respiratory tract infections and five patients with urinary tract infections were treated with HBK by drip intravenous infusion at a dose of 150 mg or 200 mg a day. Five patients showed an excellent and four good response, while one other patient responded only fairly and the other poorly. No undesirable symptoms and signs including deafness and no abnormalities in clinical laboratory findings were observed during and after administration of the drug.